Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy.
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy. Drugs. 2025 Oct; 85(10):1231-1251.
PMID: 40908381
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant. Hemasphere. 2025 Aug; 9(8):e70186.
PMID: 40838100
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood Adv. 2025 Jul 22; 9(14):3613-3616.
PMID: 40334078
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma.
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma. Leukemia. 2025 Sep; 39(9):2285-2288.
PMID: 40670674
Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.
Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma. Blood Neoplasia. 2025 Nov; 2(4):100124.
PMID: 40919481
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma.
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma. Blood Cancer J. 2025 Mar 28; 15(1):47.
PMID: 40155599
Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma.
Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma. EJHaem. 2024 Dec; 5(6):1260-1264.
PMID: 39691273
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
PMID: 39375362
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024 08 29; 144(9):955-963.
PMID: 38713888
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
PMID: 38811560